Date: November 13, 2019 at 2PM ET (11AM PT)
![TraceyMullen](https://www.abveris.com/hs-fs/hubfs/Team%20Photos/TraceyMullen.jpg?width=293&name=TraceyMullen.jpg)
Benefits of our approach:
- Rapid reagent generation timelines
- Maximal epitope coverage with DiversimAb technology
- Highly sensitive specificity screening
- Identification of high-affinity mAbs
- Neutralizing and non-neutralizing mAbs
- Flexible deliverable strategies
- All work done in the USA
Abveris has the expertise and technology advantages required to develop high-quality reagents to the trickiest biotherapeutic molecules. Join our webinar to learn more.